'I'd rather not take Prozac': Stigma and commodification in antidepressant consumer narratives

Health

Volumn 12, Issue 1, 2008, Pages 67-86

  Smardon, Regina ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Antidepressant branding; Commodification; Consumer culture; Narrative; Stigma

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; ATTITUDE TO HEALTH; DEPRESSION; FEMALE; HUMAN; INTERVIEW; MALE; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; SOCIAL PSYCHOLOGY; SOCIOLOGY;

ANTIDEPRESSIVE AGENTS; ATTITUDE TO HEALTH; DEPRESSIVE DISORDER; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; PREJUDICE; QUALITATIVE RESEARCH; SOCIOLOGY, MEDICAL;

EID: 38649109114     PISSN: 13634593     EISSN: 14617196     Source Type: Journal    
DOI: 10.1177/1363459307083698     Document Type: Article

References (69)

1. Appadurai, A. (1986). The Social life of things: commodities in cultural perspective, 85 - 110. Cambridge: Cambridge University Press.
2. Applbaum, K. (2006). Educating for global mental health: The adoption of SSRIs in Japan. In A. Petryna, A. Lakoff and A. Kleinman (Eds.), Global pharmaceuticals. Duke University Press.
3. Becker, H. (1963). Outsiders. New York: The Free Press.
4. Blum, L. and Stracuzzi, N. (2004). Gender in the Prozac nation: Popular discourse and productive femininity. Gender and Society, 18 (3). 269 - 86.
5. Brown, P. (1995). Naming and framing: The social construction of diagnosis and illness. Journal of Health and Social Behavior, (Extra Issue), 34 - 52.
6. Campbell, C. (2005). The craft consumer: Culture, craft and consumption in a postmodern society. Journal of Consumer Culture, 5 (1). 23 - 42.
7. Charmaz, K. (1983). Loss of self: A fundamental form of suffering in the chronically ill. Sociology of Health and Illness, 5 (2). 168 - 195.
8. Cohen, D., McCubbin, M., Collin, J., and Perodeau, G. (2001). Medications as social phenomena. Health: An Interdisciplinary Journal for the Study of Health, Illness and Medicine, 5 (4). 441 - 69. London: Sage.
9. Conrad, P. (2005). The shifting engines of medicalization. Journal of Health and Social Behavior, 46 (March), 3 - 14.
10. Elliott, C. and Chambers, T. (2004). Prozac as a way of life. Berkeley, CA: University of California Press.
11. Erickson, F. (2004). Talk and social theory. Cambridge: Polity Press.
12. Featherstone, M. (1991). Consumer culture and postmodernism. London: Sage.
13. Fox, R. (1977). The medicalization and demedicalization of American society. Daedalus, 106 (1). 9 - 22.
14. Frank, A. (1995). The wounded storyteller. Chicago: University of Chicago Press.
15. Frank, A. (2006). Health stories as connectors and subjectifiers. Health: An Interdisciplinary Journal for the Study of Health, Illness and Medicine, 10 (4). 421 - 40. London: Sage.
16. Garfinkel, H. (1967). Studies in ethnomethodology. Englewood Cliffs, NJ: Prentice Hall.
17. Goffman, E. (1959 a). Asylums: Essays on the social situation of mental patients and other inmates. New York: Doubleday-Anchor.
18. Goffman, E. (1959 b). The presentation of self in everyday life. New York: Doubleday-Anchor.
19. Goffman, E. (1963). Stigma. New York: Simon & Schuster.
20. Goldman, R. and Montagne, M. (1986). Marketing mind mechanics: Decoding antidepressant drug advertisements. Social Science and Medicine, 22 (10). 1047 - 58.
21. Healy, D. (1997). The anti-depressant era. Cambridge, MA: Harvard University Press.
22. Healy, D. (2004). Let them eat Prozac: The unhealthy relationship between the pharmaceutical industry and Prozac. New York: NYU Press.
23. Healy, D. (2006). The new medical Oikumene. In A. Petryna, A, Lakoff and A. Kleinman (Eds.), Global pharmaceuticals, 61 - 84. Duke University Press.
24. Hollon, M.F. (2005) Direct-to-consumer advertising: A haphazard approach to health. Promotion. JAMA. 293 (April 27). 2030 - 33.
25. Holstein, J. and Gubrium, J. (1995). The active interview. Thousand Oaks, CA: Sage.
26. Holstein, J. and Gubrium, J. (2000). The self we live by: Narrative identity in a postmodern world. New York: Oxford University Press.
27. IMS World Review (2004). http://www.imshealth.com/
28. Karp, D. (1993). Taking anti-depressant medications: Resistance, trial, commitment, conversion, disenchantment. Qualitative Sociology, 16 (4). 337 - 59.
29. Karp, D. (1996). Speaking of sadness: Depression, disconnection and the meaning of illness. Oxford: Oxford University Press.
30. Karp, D. (2001). The burden of sympathy: How families cope with mental illness. Oxford: Oxford University Press.
31. Karp, D. (2006). Is it me or is it my meds?: Living with antidepressants. Cambridge, MA: Harvard University Press.
32. Kirk, S. and Kutchins, H. (1992). The selling of the DSM: The rhetoric of science in psychiatry. NewYork: Aldine de Gruyter.
33. Kirsch, I., Moore, T., Scorboria, A. and Nicholls, S. (2002). The emperor's new drugs: An analysis of antidepressant medication data submitted to the U. S. Food and Drug Administration. Prevention and Treatment. 5, Article 23. Available at http://www.journals.apa.org/prevention/volume5/pre0050023a.html
34. Klein, N. (2000). No logo. New York: Picador.
35. Kleinman, A. (1988). The iIlness narratives: Suffering, healing, and the human condition. New York: Basic Books.
36. Kopytoff, I. (1986). The cultural biography of things: Commodification as process. In A. Appadurai (Ed.), The social life of things: Commodities in cultural perspective, 64 - 94. Cambridge: Cambridge University Press.
37. Lakoff, A. (2004). The anxieties of globalization: Antidepressant sales and the economic crisis in Argentina. Social Studies of Science, 34 (2). 247 - 69.
38. Lakoff. A. (2006). High contact: Gifts and surveillance in Argentina. In A. Petryna, A. Lakoff and A. Kleinman (Eds.), Global pharmaceuticals, 111 - 135. Duke University Press.
39. Landers, P. (2002). Drug companies push Japan to change view of depression. Wall Street Journal. October 9.
40. Lemert, E. (1962). Paranoia and the dynamics of exclusion. Sociometry, 25 (March), 220.
41. Levi -Strauss, C. (1966). The savage mind. Chicago: University of Chicago Press.
42. Lindesmith, A. (1947). Opiate addiction. Bloomington, IN: Indiana University Press.
43. Link, B., Cullen, F., Stuening, E., Shrout, P., and Dohrenwend, B. (1989). A modified labeling theory approach to mental disorders: An empirical assessment. American Sociological Review, 54 (3). 400 - 423.
44. Link, B. and Phelan, J.C. (1999). Labeling and stigma. In C. Aneshensel and J. C. Phelan (Eds.), Handbook of the sociology of mental health, 481 - 94. New York: Kluwer Academic Press.
45. Lvdahl, U.,. Riska and E. Riska. (1999). Gender display in Scandinavian and American advertising for antidepressants. Scandinavian Journal of Public Health, 27, 306 - 310.
46. Maier. W. et al. (1999). Gender differences in the prevalence of depression: A survey in primary care. Journal of Affective Disorders.
47. Mattingly, C. and Garro, L. (2000). Narrative and the cultural construction of illness and healing. Berkeley, CA: University of California Press
48. Miller, D. (1987). Material culture and mass consumption. Oxford: Blackwell.
49. Mintz, S. (1985). Sweetness and power: The place of sugar in modern history. New York: Penguin Books.
50. Montagne, M. (2001). Mass media representations as drug information for patients: The Prozac phenomenon. Substance Use and Misuse, 36 (9 / 10). 1267 - 74.
51. NIHCM (National Institute for Health Care Management Research and Education Foundation) (2002). Prescription drug expenditures in 2001: Another year of escalating costs. March 29. http://www.nihcm.org/pharm.html
52. Nichter, M. and Vuckovic, N. (1994) Agenda for an anthropology of pharmaceutical practice. Social Science and Medicine, 39 (9). 1285 - 1302.
53. Nikelly, A. (1995) Drug advertising and the medicalization of unipolar depression. Healthcare for Women International, 16 (3). 229 - 42.
54. Nolen-Hoeksema, S. (1990). Sex differences in unipolar depression: Evidence and theory. Psychological Bulletin. 101 (2). 259 - 82.
55. Phelan, J.C. and Link, B. (1999). The labeling theory of mental disorder (I): The role of social contingencies in the application of psychiatric labels. In A. Horwitz and T. Scheid (Eds.), A handbook for the study of mental health: Social contexts, theories, and system, 139 - 150. Cambridge: Cambridge University Press.
56. Ritzer, G. (2004). The globalization of nothing. Thousand Oaks, CA: Pine Forge Press.
57. Rubin, L. (2004). Merchandizing madness: Pills performance, and better living through chemistry. The Journal of Popular Culture, 38 (2). 369 - 81.
58. Scheff, T. (1966 / 1999). Being mentally ill: A sociological theory. Chicago: Aldine.
59. Schneider, J. and Conrad, P. (1980). In the closet with illness: Epilepsy, stigma potential and information control. Social Problems, 28 (1). 32 - 44.
60. Slater, D. (1997). Consumer culture and modernity. Cambridge: Polity Press.
61. Starr, Paul. (1982). The Social Transformation of American Medicine. New York, NY: Basic Books.
62. Swazey, J. (1974). Chlorpromazine: A study in therapeutic innovation. Cambridge: MIT Press.
63. Thoits, P. (1985). Self-labeling processes in mental illness: The role of emotional deviance. American Journal of Sociology, 91, 221 - 240.
64. Tulloch, J. and Lupton, D. (2002). Consuming risk, consuming science: The case of GM foods. Journal of Consumer Culture, 2 (3). 363 - 83.
65. Urban, G. (2001). Metaculture: How culture moves through the world. Minneapolis, MN: University of Minnesota Press.
66. Van der Geerst, S., Reynolds White, S. and Hardon, A. (1996). The anthropology of pharmaceuticals: A biographical approach. Annual Review of Anthropology, 25 (1). 153 - 78.
67. Vuckovic, N. and Nichter, M. (1997). Changing patterns of pharmaceutical practice in the U. S. Social Science and Medicine, 44 (9). 1285 - 302.
68. Wehfritz, G. and Itoi, K. (2001). Prozac pipeline. Newsweek International August 20 p. 23.
69. Zola, I. (1973). Pathways to the doctor. Social Science and Medicine, 7 (9). 677 - 89.